Juno stock drops on report of lackluster immunotherapy results on solid tumors

April 20, 2015 8:37 PM

2 0

Juno stock drops on report of lackluster immunotherapy results on solid tumors

Seattle biotech Juno Therapeutics' stock closed down 13 percent today after data showed lackluster results for treating solid tumors with immunotherapy, an approach that Juno is exploring.

Data presented from a Phase 1 study by Swiss pharmaceutical company Novartis and the University of Pennsylvania showed immunotherapy didn't seem to "have much longevity or efficacy" treating solid tumor cancers, financial news site The Street reported this morning.

Also read: Apple tells feds ‘new entrants’ to auto industry should get same testing rights as incumbents

Read more

To category page

Loading...